Viewing nowCombinationJanudiem Extended-Release Tablet 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.

MFDS item code 202300599 · Approved 2023.02.17 · Insurance code 643705450
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to aid blood sugar control in patients with type 2 diabetes by combining sitagliptin and metformin. It helps in effectively managing blood sugar while adhering to dietary and exercise regimens. Regular intake of this medication will significantly assist in maintaining stable blood sugar levels. It is used for improving blood sugar levels in patients with type 2 diabetes.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with food once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole. Do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at their current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined taking into account the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains both sitagliptin and metformin, used in the treatment of diabetes. First, the sitagliptin component can cause rare but serious allergic reactions; if symptoms like rash, hives, or shortness of breath occur, stop taking the medication immediately and consult a doctor. Acute pancreatitis may also occur, thus if symptoms such as abdominal pain, nausea, or vomiting arise, immediate medical attention is required. The metformin component can cause a rare side effect known as lactic acidosis, which is very dangerous; if symptoms such as difficulty breathing, muscle pain, or extreme fatigue appear, seek treatment immediately. This medication should not be administered to patients with moderate to severe renal impairment, acute heart failure, or those with severe infections or dehydration. Prior to and after examinations using iodine-based contrast materials, the intake of this medication should be temporarily suspended, and intake should resume only after confirming that renal function is normal. It is considered safe not to use this medication in pregnant or breastfeeding women and in children under 18 years of age. While taking this medication, it is essential to regularly check not only blood sugar levels but also renal function and blood test results, as a deficiency in Vitamin B12 may occur, necessitating periodic testing. Excessive alcohol consumption should be avoided during treatment, as acute or chronic alcohol intake may increase the risk of lactic acidosis. There is also a risk of hypoglycemia, so caution is needed when skipping meals or engaging in intense exercise, and when used in combination with other blood sugar-lowering agents, particularly be cautious of symptoms of hypoglycemia. Before surgery, the use of this medication should be paused for a period, and after surgery, it should only be resumed once oral intake has returned to normal and renal function has improved. Lastly, this medication may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, etc.), headaches, and cold-like symptoms; if these symptoms persist, consult a physician.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, thus it should be stored in a sealed container. Additionally, it is important to store this medication at room temperature between 1 and 30 degrees Celsius to maintain its efficacy.
Bright blue, double convex, oval-shaped extended-release film-coated tablets
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.37mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.